FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2056557576> ?p ?o ?g. }

• W2056557576 endingPage "223" @default.
• W2056557576 startingPage "216" @default.
• W2056557576 abstract "Due to ongoing neuropsychiatric adverse events in some efavirenz (EFV)-treated patients, a switch to an alternative non-nucleoside reverse transcriptase inhibitor may be considered. Rilpivirine (RPV) has been coformulated as a single-tablet regimen (STR) with emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), and the components have demonstrated noninferior efficacy to EFV+FTC/TDF, good tolerability profile, and high adherence. After discontinuation, EFV has an extended inductive effect on cytochrome P450 (CYP) 3A4 that, after switching, may reduce RPV exposures and adversely impact clinical outcomes.This study examines the clinical implications of reduced RPV exposures with concomitant FTC/TDF and declining EFV exposures when patients, intolerant to EFV, switch from EFV/FTC/TDF to RPV/FTC/TDF.This 48-week, phase 2b, open-label, multicenter study evaluated the efficacy and safety of switching from EFV/FTC/TDF (≥3 months duration) to RPV/FTC/TDF. Virologic suppression (HIV-1 RNA <50 copies/mL), safety, and EFV and RPV pharmacokinetics were assessed.At weeks 12 and 24, all 49 dosed subjects remained suppressed on RPV/FTC/TDF. At week 48, 46 (93.9%) subjects remained suppressed and virologic failure occurred in 2/49 (4.1%) subjects with no emergence of resistance. EFV concentrations were above the 90th percentile for inhibitory concentration (IC90) for several weeks after EFV discontinuation, and RPV exposures were in the range observed in phase 3 studies by approximately 2 weeks post switch. No subjects discontinued the study due to an adverse event.Switching from EFV/FTC/TDF to RPV/FTC/ TDF was a safe, efficacious option for virologically suppressed HIV-infected patients with EFV intolerance wishing to remain on an STR." @default.
• W2056557576 created "2016-06-24" @default.
• W2056557576 creator A5000170374 @default.
• W2056557576 creator A5001632717 @default.
• W2056557576 creator A5020826937 @default.
• W2056557576 creator A5025427459 @default.
• W2056557576 creator A5030772735 @default.
• W2056557576 creator A5037765362 @default.
• W2056557576 creator A5042040728 @default.
• W2056557576 creator A5058338096 @default.
• W2056557576 creator A5061747057 @default.
• W2056557576 creator A5066658805 @default.
• W2056557576 creator A5082622296 @default.
• W2056557576 date "2013-10-01" @default.
• W2056557576 modified "2023-09-26" @default.
• W2056557576 title "Efficacy and Safety 48 Weeks after Switching from Efavirenz to Rilpivirine Using Emtricitabine/Tenofovir Disoproxil Fumarate–Based Single-Tablet Regimens" @default.
• W2056557576 cites W1550111394 @default.
• W2056557576 cites W1976641979 @default.
• W2056557576 cites W1996747410 @default.
• W2056557576 cites W2001745085 @default.
• W2056557576 cites W2004487100 @default.
• W2056557576 cites W2055351311 @default.
• W2056557576 cites W2057394385 @default.
• W2056557576 cites W2116410566 @default.
• W2056557576 cites W2136381344 @default.
• W2056557576 cites W2143166782 @default.
• W2056557576 cites W2147357250 @default.
• W2056557576 cites W2148750104 @default.
• W2056557576 cites W2159328065 @default.
• W2056557576 doi "https://doi.org/10.1310/hct1405-216" @default.
• W2056557576 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24144898" @default.
• W2056557576 hasPublicationYear "2013" @default.
• W2056557576 type Work @default.
• W2056557576 sameAs 2056557576 @default.
• W2056557576 citedByCount "64" @default.
• W2056557576 countsByYear W20565575762013 @default.
• W2056557576 countsByYear W20565575762014 @default.
• W2056557576 countsByYear W20565575762015 @default.
• W2056557576 countsByYear W20565575762016 @default.
• W2056557576 countsByYear W20565575762017 @default.
• W2056557576 countsByYear W20565575762018 @default.
• W2056557576 countsByYear W20565575762019 @default.
• W2056557576 countsByYear W20565575762020 @default.
• W2056557576 countsByYear W20565575762022 @default.
• W2056557576 crossrefType "journal-article" @default.
• W2056557576 hasAuthorship W2056557576A5000170374 @default.
• W2056557576 hasAuthorship W2056557576A5001632717 @default.
• W2056557576 hasAuthorship W2056557576A5020826937 @default.
• W2056557576 hasAuthorship W2056557576A5025427459 @default.
• W2056557576 hasAuthorship W2056557576A5030772735 @default.
• W2056557576 hasAuthorship W2056557576A5037765362 @default.
• W2056557576 hasAuthorship W2056557576A5042040728 @default.
• W2056557576 hasAuthorship W2056557576A5058338096 @default.
• W2056557576 hasAuthorship W2056557576A5061747057 @default.
• W2056557576 hasAuthorship W2056557576A5066658805 @default.
• W2056557576 hasAuthorship W2056557576A5082622296 @default.
• W2056557576 hasConcept C112705442 @default.
• W2056557576 hasConcept C126322002 @default.
• W2056557576 hasConcept C142462285 @default.
• W2056557576 hasConcept C159047783 @default.
• W2056557576 hasConcept C197934379 @default.
• W2056557576 hasConcept C2778375690 @default.
• W2056557576 hasConcept C2778715236 @default.
• W2056557576 hasConcept C2778723075 @default.
• W2056557576 hasConcept C2779778239 @default.
• W2056557576 hasConcept C2781432083 @default.
• W2056557576 hasConcept C2993143319 @default.
• W2056557576 hasConcept C3013748606 @default.
• W2056557576 hasConcept C71924100 @default.
• W2056557576 hasConcept C98274493 @default.
• W2056557576 hasConceptScore W2056557576C112705442 @default.
• W2056557576 hasConceptScore W2056557576C126322002 @default.
• W2056557576 hasConceptScore W2056557576C142462285 @default.
• W2056557576 hasConceptScore W2056557576C159047783 @default.
• W2056557576 hasConceptScore W2056557576C197934379 @default.
• W2056557576 hasConceptScore W2056557576C2778375690 @default.
• W2056557576 hasConceptScore W2056557576C2778715236 @default.
• W2056557576 hasConceptScore W2056557576C2778723075 @default.
• W2056557576 hasConceptScore W2056557576C2779778239 @default.
• W2056557576 hasConceptScore W2056557576C2781432083 @default.
• W2056557576 hasConceptScore W2056557576C2993143319 @default.
• W2056557576 hasConceptScore W2056557576C3013748606 @default.
• W2056557576 hasConceptScore W2056557576C71924100 @default.
• W2056557576 hasConceptScore W2056557576C98274493 @default.
• W2056557576 hasIssue "5" @default.
• W2056557576 hasLocation W20565575761 @default.
• W2056557576 hasLocation W20565575762 @default.
• W2056557576 hasOpenAccess W2056557576 @default.
• W2056557576 hasPrimaryLocation W20565575761 @default.
• W2056557576 hasRelatedWork W1988843882 @default.
• W2056557576 hasRelatedWork W2009822178 @default.
• W2056557576 hasRelatedWork W2052360673 @default.
• W2056557576 hasRelatedWork W2099826019 @default.
• W2056557576 hasRelatedWork W2161452009 @default.
• W2056557576 hasRelatedWork W2323941313 @default.
• W2056557576 hasRelatedWork W2477756378 @default.
• W2056557576 hasRelatedWork W2729471497 @default.
• W2056557576 hasRelatedWork W4210413064 @default.

• next